Resources
About Us
Home Report
Store
Europe NGS Automation Market
Europe NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Forecast to 2030
Report ID:MRHC - 104961 Pages: 120 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Europe NGS Automation Market is projected to reach $380.4 million by 2030, at a CAGR of 13.4% from 2024 to 2030. Next-generation sequencing (NGS) includes sample pre-processing, library preparation, sequencing, and bioinformatics. The library preparation step is critical in NGS workflow; however, it is still time-consuming and repetitive despite ongoing technical advancements in high-throughput sequencing. The library preparation step has numerous repetitive steps that require small volumes to be pipetted with high precision. This process makes it highly prone to manual errors, compromising the entire NGS process. Automation of library preparation can increase efficiency, generate more consistent results, and increase lab efficiency. NGS automation also helps maintain turnaround times and increase sample throughput.
The main factors driving the NGS automation market are the increasing demand for automation in NGS workflow, the rising incidences of cancer, and the increasing R&D investments and healthcare expenditure. Furthermore, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market.
However, the high cost of automation workstations is expected to restrain the growth of this market to a notable extent. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges to the growth of this market.
Click here to: Get Free Sample Pages of this Report
Growing Demand for Optimized & Streamlined NGS Workflows to Drive Adoption
The emergence of next-generation sequencing (NGS) technology has led to a significant decrease in DNA sequencing costs, making the technology accessible to scientists worldwide. However, despite the significant decrease in costs, there are still some challenges in the manual processes used in sequencing technology. The library preparation step is highly time-consuming and prone to human error, making the process inefficient for genomics laboratories in terms of time and cost. Automating such processes can increase efficiency and reduce sequencing costs.
Automating NGS library preparation helps researchers improve their library quality and achieve consistent yields, enabling reliable and reproducible NGS data generation. NGS automation also enhances efficiency in terms of time and cost. The risk of contamination is greatly reduced by reducing human interactions with the reagents and samples. The rising need for accuracy, scalability, and compliance with regulatory standards is expected to drive the demand for NGS automation in Europe.
Rising Prevalence of Cancer to Drive Market Growth
Cancer is a prominent cause of death and a major obstacle to improving life expectancy in every country worldwide. The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women succumb to the disease. Europe also faces a similar scenario of rising cancer prevalence. According to IARC, the number of new cancer cases in Europe is estimated to increase from 4.39 million in 2020 to 4.91 million by 2030.
NGS allows comprehensive profiling of a patient's tumor DNA, which guides the development of personalized treatment plans. As the number of cancer cases continues to rise, there is a growing need for NGS automation solutions to efficiently process and analyze the vast amount of genetic data generated in cancer diagnostics and research. Additionally, the rising cancer prevalence creates a high demand for new cancer drugs. Therefore, pharmaceutical and biotechnology companies require efficient and high-throughput NGS automation solutions for research and development.
Thus, the rising prevalence of cancer and increasing efforts to develop targeted treatment approaches are expected to drive the NGS automation market in Europe.
Key Findings in the Europe NGS Automation Market Study:
The Workstation/Robotic Platform Segment to Dominate the Market in 2024
Based on product, the Europe NGS automation market is segmented into workstations/robotic platforms and reagents & consumables. In 2024, the workstations/robotic platforms segment is expected to account for the larger share of the NGS automation market in Europe. The large market share of this segment is attributed to factors such as the increasing pharmaceutical R&D expenditure and the rising demand for automation of NGS library preparation due to its benefits, such as increased efficiency and the ability to generate consistent and reproducible results.
The Drug Discovery Segment to Dominate the Europe NGS Automation Market in 2024
Based on application, the Europe NGS automation market is segmented into drug discovery, clinical diagnostics (oncology, infectious diseases, reproductive health, and other clinical diagnostics), and other applications. In 2024, the drug discovery segment is expected to account for the largest share of the NGS automation market in Europe. The large market share of this segment is attributed to the increased use of NGS technologies in drug discovery and the potential of NGS to cut down drug development costs and reduce the duration of drug discoveries. Next-generation sequencing has ushered in a new era of gene-based drug development by enabling high-throughput analysis of genotype-phenotype relationships in human populations, boosting the demand for NGS automation.
The Whole Genome Sequencing Segment to Dominate the Europe NGS Automation Market in 2024
Based on sequencing type, the NGS Automation market is segmented into whole genome sequencing, whole exome sequencing, targeted genome sequencing, and other sequencing types. In 2024, the whole genome sequencing segment is expected to account for the largest share of the NGS automation market in Europe. The large market share of this segment is attributed to the rising need to lower the per-sample cost of whole-genome sequencing by automating the NGS library preparation. Library preparation activities such as DNA extraction, quantification, fragmentation, normalization, purification, and quality control are labor-intensive and slow down the generation of sequencing data; hence, there is a rising demand for the adoption of NGS automation solutions.
The Pharmaceutical and Biotechnology Companies Segment to Dominate the Europe NGS Automation Market in 2024
Europe NGS Automation market is segmented into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the NGS automation market in Europe. The large share of this segment is attributed to the increasing pharmaceutical and biotechnology R&D expenditure, growing adoption of NGS in drug discovery and development, and increased government funding for research activities. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in advanced NGS automation systems are one of the major factors driving the growth of this segment.
Key Players
The report includes a competitive landscape based on an in-depth assessment of offerings and growth strategies adopted by key market players in the last 3–4 years.The key players operating in the Europe NGS Automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).
Scope of the Report:
Europe NGS Automation Market, by Product
- Workstation/Robotic Platform
- Reagents & Consumables
Europe NGS Automation Market, by Application
- Drug Discovery
- Clinical Diagnostics
- Oncology
- Infectious Diseases
- Reproductive Health
- Other Clinical Diagnostics
- Other Applications
Europe NGS Automation Market, by Sequencing Type
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Genome Sequencing
- Other Sequencing Types
Europe NGS Automation Market, by End User
- Hospitals & Diagnostic Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Others End Users
Europe NGS Automation Market, by Country
- Germany
- France
- U.K.
- Italy
- Spain
- Switzerland
- Netherlands
- Belgium
- Rest of Europe (RoE)
Key questions answered in the report:
The Europe NGS automation market report covers the market sizes & forecasts based on product, application, sequencing type, end user, and geography. The NGS automation market studied in this report involves the value analysis of various segments and subsegments of Europe NGS automation at the regional and country levels.
The Europe NGS automation market is projected to reach $380.4 million by 2030, at a CAGR of 13.4% during the forecast period of 2024–2030.
Based on type, the NGS automation market is segmented into workstation/robotic platform and reagents & consumables. In 2024, the workstation/robotic platform segment is estimated to account for the largest share of the NGS automation market in Europe.
Based on application, the NGS automation market is segmented into drug discovery, clinical diagnostics, and other applications. In 2024, the drug discovery segment is estimated to account for the largest share of the NGS automation market in Europe.
Based on sequencing type, the NGS automation market is segmented into whole genome sequencing, whole exome sequencing, targeted genome sequencing, and other sequencing types. In 2024, the whole genome sequencing segment is estimated to account for the largest share of the NGS automation market in Europe.
Based on end user, the NGS automation market is segmented into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is estimated to account for the largest share of the NGS automation market in Europe.
The growth of this market is attributed to factors such as the increasing demand for automation in NGS workflow, the rising incidences of cancer, and the increasing R&D investments and healthcare expenditure. In addition, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market.
The high cost of automation workstations is expected to hinder the growth of this market to a notable extent. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges to the growth of this market.
The key players operating in the NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Demand for Automation in NGS Workflow
4.2.2. Rising Incidences of Cancer
4.2.3. Increasing R&D Investments and Healthcare Expenditure in Europe
4.3. Restraints
4.3.1. High Cost of Automation Workstations
4.4. Opportunity
4.4.1. Rising Number of Collaborations Between Companies to Develop Library Preparation Protocols
4.4.2. Increasing Applications of Next-Generation Sequencing
4.5. Challenges
4.5.1. Dearth of High-skilled Personnel for Operating Automation Software
4.5.2. Regulatory & Standardization Concerns in Diagnostic Testing
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Porter’s Five Forces Analysis
4.9. Industry and Technology Trends
5. Europe NGS Automation Market Assessment—by Product
5.1. Overview
5.2. Workstations/Robotic Platforms
5.3. Reagents & Consumables
6. Europe NGS Automation Market Assessment—by Application
6.1. Overview
6.2. Drug Discovery
6.3. Clinical Diagnostics
6.3.1. Oncology
6.3.2. Infectious Diseases
6.3.3. Reproductive Health
6.3.4. Other Clinical Diagnostics
6.4. Other Applications
7. Europe NGS Automation Market Assessment—by Sequencing Type
7.1. Overview
7.2. Whole Genome Sequencing
7.3. Whole Exome Sequencing
7.4. Targeted Genome Sequencing
7.5. Other Sequencing Types
8. Europe NGS Automation Market Assessment—by End User
8.1. Overview
8.2. Hospitals & Diagnostic Laboratories
8.3. Pharmaceutical & Biotechnology Companies
8.4. Academics & Research Institutes
8.5. Other End Users
9. Europe NGS Automation Market Assessment—by Geography
9.1. Overview
9.2. Germany
9.3. France
9.4. U.K.
9.5. Italy
9.6. Spain
9.7. Switzerland
9.8. Netherlands
9.9. Belgium
9.10. Rest of Europe (RoE)
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis, by Key Player/Key Market Ranking (2022)
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
11.1. Agilent Technologies, Inc.
11.2. Danaher Corporation
11.3. Eppendorf AG
11.4. Hamilton Company
11.5. PerkinElmer, Inc.
11.6. Tecan Group Ltd.
11.7. PRIMADAG SAS
11.8. BRAND GMBH + CO KG
11.9. Hudson Robotics
11.10. SPT Labtech
11.11. Thermo Fisher Scientific, Inc.
11.12. F. Hoffmann-La Roche Ltd
(Note: SWOT analysis will be provided for the top 5 companies only)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Europe NGS Automation Market Drivers: Impact Analysis (2024–2030)
Table 2 Europe NGS Automation Market Restraints: Impact Analysis (2024–2030)
Table 3 Europe NGS Automation Market Opportunities: Impact Analysis (2024–2030)
Table 4 Europe NGS Automation Market Challenges: Impact Analysis (2024–2030)
Table 5 NGS Automation Workstation: Pricing Details
Table 6 Europe NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 7 Europe NGS Automation Workstation/Robotic Platform Market, by Country, 2021–2030 (USD Million)
Table 8 Europe NGS Automation Reagents & Consumables Market, by Country, 2021–2030 (USD Million)
Table 9 Europe NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 10 Europe NGS Automation Market for Drug Discovery, by Country, 2021–2030 (USD Million)
Table 11 Europe NGS Automation Market for Clinical Diagnostics, by Type, 2021–2030 (USD Million)
Table 12 Europe NGS Automation Market for Clinical Diagnostics, by Country, 2021–2030 (USD Million)
Table 13 Europe NGS Automation Market for Oncology, by Country, 2021–2030 (USD Million)
Table 14 Europe NGS Automation Market for Infectious Diseases, by Country, 2021–2030 (USD Million)
Table 15 Europe NGS Automation Market for Reproductive Health, by Country, 2021–2030 (USD Million)
Table 16 Europe NGS Automation Market for Other Clinical Diagnostics, by Country, 2021–2030 (USD Million)
Table 17 Europe NGS Automation Market for Other Applications, by Country, 2021–2030 (USD Million)
Table 18 Europe NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 19 Europe NGS Automation Market for Whole Genome Sequencing, by Country, 2021–2030 (USD Million)
Table 20 Europe NGS Automation Market for Whole Exome Sequencing, by Country, 2021–2030 (USD Million)
Table 21 Europe NGS Automation Market for Targeted Genome Sequencing, by Country, 2021–2030 (USD Million)
Table 22 Europe NGS Automation Market for Other Sequencing Types, by Country, 2021–2030 (USD Million)
Table 23 Europe NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 24 Europe NGS Automation Market for Hospitals & Diagnostic Laboratories, by Country, 2021–2030 (USD Million)
Table 25 Europe NGS Automation Market for Pharmaceutical & Biotechnology Companies, by Country, 2021–2030 (USD Million)
Table 26 Europe NGS Automation Market for Academic & Research Institutes, by Country, 2021–2030 (USD Million)
Table 27 Europe NGS Automation Market for Other End Users, by Country, 2021–2030 (USD Million)
Table 28 Europe NGS Automation Market, by Country, 2021–2030 (USD Million)
Table 29 Germany: Key Macro & Micro Indicators
Table 30 Germany: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 31 Germany: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 32 Germany: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 33 Germany: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 34 Germany: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 35 France: Key Macro & Micro Indicators
Table 36 France: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 37 France: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 38 France: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 39 France: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 40 France: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 41 U.K.: Key Macro & Micro Indicators
Table 42 U.K.: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 43 U.K.: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 44 U.K.: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 45 U.K.: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 46 U.K.: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 47 Italy: Key Macro & Micro Indicators
Table 48 Italy: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 49 Italy: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 50 Italy: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 51 Italy: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 52 Italy: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 53 Spain: Key Macro & Micro Indicators
Table 54 Spain: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 55 Spain: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 56 Spain: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 57 Spain: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 58 Spain: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 59 Switzerland: Key Macro & Micro Indicators
Table 60 Switzerland: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 61 Switzerland: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 62 Switzerland: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 63 Switzerland: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 64 Switzerland: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 65 Netherlands: Key Macro & Micro Indicators
Table 66 Netherlands: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 67 Netherlands: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 68 Netherlands: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 69 Netherlands: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 70 Netherlands: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 71 Belgium: Key Macro & Micro Indicators
Table 72 Belgium: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 73 Belgium: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 74 Belgium: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 75 Belgium: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 76 Belgium: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 77 Rest of Europe: NGS Automation Market, by Product, 2021–2030 (USD Million)
Table 78 Rest of Europe: NGS Automation Market, by Application, 2021–2030 (USD Million)
Table 79 Rest of Europe: Clinical Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 80 Rest of Europe: NGS Automation Market, by Sequencing Type, 2021–2030 (USD Million)
Table 81 Rest of Europe: NGS Automation Market, by End User, 2021–2030 (USD Million)
Table 82 Recent Developments, by Company (2019–2022)
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Europe NGS Automation Market, by Product, 2024 Vs. 2030 (USD Million)
Figure 8 Europe NGS Automation Market, by Application, 2024 Vs. 2030 (USD Million)
Figure 9 Europe NGS Automation Market, by Sequencing Type, 2024 Vs. 2030 (USD Million)
Figure 10 Europe NGS Automation Market, by End User, 2024 Vs. 2030 (USD Million)
Figure 11 Market Dynamics: Europe NGS Automation Market
Figure 12 Europe NGS Automation Market, by Product, 2024 Vs. 2030 (USD Million)
Figure 13 Europe NGS Automation Market, by Application, 2024 Vs. 2030 (USD Million)
Figure 14 Europe NGS Automation Market, by Sequencing Type, 2024 Vs. 2030 (USD Million)
Figure 15 Europe NGS Automation Market, by End User, 2024 Vs. 2030 (USD Million)
Figure 16 Europe: NGS Automation Market Snapshot
Figure 17 Key Growth Strategies Adopted by Leading Players (2020–2024)
Figure 18 Europe NGS Automation Market: Competitive Benchmarking Based on Product
Figure 19 Europe NGS Automation Market: Competitive Benchmarking Based on Country
Figure 20 Europe NGS Automation Market: Competitive Dashboard
Figure 21 Market Share Analysis: Europe NGS Automation Market (2022)
Figure 22 Agilent Technologies, Inc.: Financial Overview (2021)
Figure 23 Danaher Corporation: Financial Overview (2021)
Figure 24 Eppendorf AG: Financial Overview (2020)
Figure 25 PerkinElmer, Inc.: Financial Overview (2020)
Figure 26 Tecan Group Ltd.: Financial Overview (2020)
Figure 27 Thermo Fisher Scientific, Inc.: Financial Overview (2021)
Figure 28 F. Hoffmann-La Roche Ltd: Financial Overview (2021)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Pharmacy Automation Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Aug-2024
North America NGS Automation Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
NGS Market: Industry Outlook - Global Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Jul-2024
Europe NGS Market - Opportunity Analysis and Industry Forecasts (2024-2030)
Published Date: Jul-2024
North America NGS Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
